ClinicalTrials.gg
Enrolling by invitationNCT04429607Updated Jul 1, 2026

Treatment of Sebaceous Hyperplasia With PDL and Nd:YAG Versus Erbium:YAG: A Randomized Controlled Trial

A Phase 2 interventional study of Erbium:YAG Laser and Pulsed Dye Laser in Sebaceous Hyperplasia, sponsored by Northwestern University. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by Northwestern University · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Hyperplasia with a site in United States — 3 open to participants now, 4 under way, none of them phase 3. Hyperplasia · United States.

Planned enrollment
14th of 21
18 · median 31
Started
2025
with 1 other
Phase 2
3 of 30
2 open now
Registered
27th of 30
by date

Among the 30 studies in Hyperplasia with a site in United States, this one is the 14th largest by planned enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2025, is one of 3 in phase 2, and was the 27th registered.

Hyperplasia

76 studies on the registry are indexed under Hyperplasia; 9 are open to participants now.

Browse Hyperplasia studies →

Open to participants now

3 of the 30 studies in Hyperplasia with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Hyperplasia studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Hyperplasia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to compare treatment of sebaceous hyperplasia with pulsed dye laser (PDL) plus neodymium doped yttrium aluminum garnet laser (Nd:YAG) versus erbium doped yttrium aluminum garnet (erbium:YAG) laser versus electrodesiccation and curettage (ED\&C).

This is a randomized clinical trial. Approximately 18 participants will enrolled. Each participant will have their sebaceous hyperplasia lesions randomized to receive either Erbium:YAG, PDL plus Nd:YAG, or ED\&C treatment. Solitary lesions will be randomized to a group, thus, a patient may receive all three treatments, each on different lesions. Lesions will be treated twice, 2-6 weeks after the first treatment. Lesion size and count will be measured before treatment and at follow-up 4-12 weeks after the first treatment. This study is a pilot study designed to determine the feasibility of these procedures.

Subjects currently living in the Chicago metropolitan area and meet inclusion/exclusion criteria will be considered for enrollment.

03

Conditions studied

  • Sebaceous Hyperplasia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥18 years of age
  2. Receiving cosmetic treatment for sebaceous hyperplasia
  3. In good general health as assessed by the investigator
  4. Participants must have the ability to understand and the willingness to sign a written prior to registration on study

Exclusion criteria

Exclusion Criteria:

  1. Patient pregnant or nursing
  2. Patient with history of poor wound healing that would result in hypertrophic scar or keloid at the discretion of the physician
  3. Patient with recent sun exposure that would result in pigment changes at the discretion of the physician
  4. Subject unwilling to sign an IRB approved consent form
  5. Participants who are unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function are not eligible
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
18 participants (estimated)

Study arms

  • Active comparator
    Erbium:YAG Laser

    Solitary lesions will be randomized to a group, thus, a patient may receive all three treatments, each on different lesions. Patients will undergo two total treatment sessions at 2-6 week intervals.

    Device: Erbium:YAG Laser

  • Active comparator
    PDL plus Nd:YAG

    Solitary lesions will be randomized to a group, thus, a patient may receive all three treatments, each on different lesions. Patients will undergo two total treatment sessions at 2-6 week intervals.

    Device: Pulsed Dye Laser · Device: Nd:YAG Laser

  • Active comparator
    ED&C treatment

    Solitary lesions will be randomized to a group, thus, a patient may receive all three treatments, each on different lesions. Patients will undergo two total treatment sessions at 2-6 week intervals.

    Procedure: Electrodessication and curettage

Interventions

  • DeviceErbium:YAG Laser

    Erbium:YAG 2940nm will be performed using single spot, multiple pulses on lesions.

  • DevicePulsed Dye Laser

    PDL will be performed using settings of 6-10 J/s2 on lesions.

    Also known as: PDL

  • DeviceNd:YAG Laser

    Nd:YAG 1064nm will be performed using settings of 60-110 J/s2 on lesions.

  • ProcedureElectrodessication and curettage

    Electrodessication and curettage will be performed using an epilating needle, followed by curettage on lesions.

    Also known as: ED&C

06

What researchers measure

Primary outcomes

  1. Change in size of sebaceous hyperplasia

    Change in size of sebaceous hyperplasia from baseline to 4-12 weeks after first treatment by measuring length and width in mm of each lesion.

    Time frame: 4-12 weeks

  2. Change in sebaceous hyperplasia lesion count

    Change in sebaceous hyperplasia lesion count from baseline to 4-12 weeks after first treatment

    Time frame: 4-12 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Dec 2026, 14 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2020
First posted
Jun 12, 2020
StartActual
Oct 23, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jul 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04429607
Responsible party
Murad Alam (Professor of Dermatology, Northwestern University) — Principal investigator
First posted
Jun 12, 2020
Start date
Oct 23, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jul 1, 2026

Study contacts

Murad Alam, MD
principal investigator · Northwestern University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion